News Releases

Announcements

Medtronic and Qualcomm Collaborate to Aim to Improve Care and Health Outcomes for People with Type 2 Diabetes

May 25, 2016

Dublin and San Diego – May 25, 2016 - Medtronic plc (NYSE:MDT) and Qualcomm Incorporated (NASDAQ:QCOM) through its wholly-owned subsidiary, Qualcomm Life, Inc., today announced a global, multi-year collaboration to jointly develop future generation continuous glucose monitoring (CGM) systems that aim to improve health outcomes for people with diabetes. By giving insights to doctors and people with type 2 diabetes concerning glucose levels, the companies intend to enable more informed care, especially for those who do not have control of their diabetes today. The collaboration seeks to leverage Medtronic's market-leadership in diabetes management and Qualcomm Life's expertise in developing reference designs for wireless, single-use and small integrated modules to create more affordable, easier-to-use CGM systems, including a new sensor and smaller design that can provide near real-time and retrospective glucose data.

Read more >

New Data Shows Benefits of Medtronic Insulin Pumps for People with Type 2 Diabetes

April 13, 2016

Dublin – April 13, 2016 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the publication of new data in Diabetes, Obesity and Metabolism from the continuation phase of the OpT2mise study, providing further clinical evidence in support of insulin pumps for people with insulin-requiring type 2 diabetes. The OpT2mise study is the largest randomized controlled trial to compare the efficacy and safety of insulin pump therapy versus multiple daily injections (MDI) for poorly controlled type 2 patients.

Read more >

Medtronic Named One of the World’s Most Admired Companies

February 19, 2016

Dublin - February 19, 2016 - Fortune magazine announced today that Medtronic is included on its list of the World's Most Admired Companies for 2016. The list is considered one of the leading measures of corporate reputation among the world’s largest companies. Medtronic is ranked second in the Medical Products and Equipment category.

Read more >

Medtronic's iPro(TM)2 Professional CGM Shows Benefits for People with Type 2 Diabetes

February 5, 2016

MILAN - February 5, 2016 - A retrospective analysis of the iPro2 Professional CGM from Medtronic plc (NYSE:MDT), the global leader in medical technology, demonstrates that patients with type 2 diabetes experience high rates of glycemic variability, hypoglycemia and hyperglycemia regardless of whether they manage their diabetes with diet/exercise, oral medication or insulin. Using this actionable iPro2 Professional CGM information, physicians can make therapy adjustments, recommendations and educational decisions for their patients to help improve glucose control. The results of the analysis were featured in an oral presentation at the 9th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2016).

Read more >

Medtronic and Chengdu Sign Insulin Pump Manufacturing Agreement

January 11, 2016

DUBLIN and CHENGDU, China - January 11, 2016 - Medtronic plc (NYSE:MDT), the global leader in medical technology, has formed a partnership with the Chengdu municipal government to manufacture and deploy advanced diabetes therapies in Chengdu, China.

Read more >

View all Announcements >





Media Inquiries

For media inquiries pertaining to the Diabetes Group of Medtronic, please contact:

Pamela Reese
Senior Manager, Communications
818-576-3398
pamela.s.reese@medtronic.com

For all other media inquiries please select the appropriate Global Public and Media Relations contact